Small Cell Lung Cancer News and Research

RSS

Small cell lung cancer is a disease in which malignant (cancer) cells form in the tissues of the lung. Small cell lung cancer is an aggressive (fast-growing) cancer that can spread to other parts of the body. The cancer cells look small and oval-shaped when looked at under a microscope.

Lung cancer spread ‘uncommon’ outside of tumour-bearing segment

Lung cancer does not often spread to areas outside of the tumour-bearing segment of the lung when there is no evidence of extrapulmonary nodal metastasis, the tumour is small and peripheral or it has ground glass opacity, study findings show.

21 Mar 2014

NSCLC gene fusion testing, targeted crizotinib – not yet cost effective

Genomic fusion testing for echinoderm microtubule-associated protein-like 4 and anaplastic lymphoma kinase genes plus targeted first-line crizotinib is not a cost effective treatment strategy for patients with advanced non-squamous non-small-cell lung cancer, shows a Canadian analysis.

20 Mar 2014

Investigational vaccine reduces number of tumors in mice with lung cancer

Researchers at UC Davis have found that the investigational cancer vaccine tecemotide, when administered with the chemotherapeutic cisplatin, boosted the immune response and reduced the number of tumors in mice with lung cancer.

20 Mar 2014

Researchers use "big data" analytics to predict triple-negative breast cancer and other cancers with 95% accuracy

Researchers at Case Western Reserve University and colleagues used "big data" analytics to predict if a patient is suffering from aggressive triple-negative breast cancer, slower-moving cancers or non-cancerous lesions with 95 percent accuracy.

19 Mar 2014

Findings reveal potential drug targets for small cell lung cancer

Cancer cells undergo extensive genetic alterations as they grow and spread through the body. Some of these mutations, known as "drivers," help spur cells to grow out of control, while others ("passengers") are merely along for the ride.

17 Mar 2014

AnaptysBio announces strategic immuno-oncology collaboration with TESARO

AnaptysBio, Inc., a leader in the discovery and development of therapeutic antibodies, today announced a strategic immuno-oncology collaboration with TESARO, Inc., an oncology-focused biopharmaceutical company.

13 Mar 2014

Synta Pharmaceuticals' Hsp90 inhibitor ganetespib selected for study in I-SPY 2 TRIAL

Synta Pharmaceuticals Corp. and QuantumLeap Healthcare Collaborative today announced that Synta's lead drug candidate, the Hsp90 inhibitor ganetespib, has been selected for study in the I-SPY 2 TRIAL (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2).

11 Mar 2014

Exosome Diagnostics closes Series B financing round with the raising of $27 million

Exosome Diagnostics today announced the initial close of its Series B financing round with the raising of $27 million. Proceeds will be used to advance development of the Company's proprietary platform technology and commercial programs for non-invasive, fluid-based molecular diagnostics in oncology, neurodegenerative diseases and other clinical areas.

11 Mar 2014

Bayer and Onyx announce Phase 3 trial evaluating use of NEXAVAR for patients with HCC after local ablation

Bayer HealthCare Pharmaceuticals Inc. and Onyx Pharmaceuticals, Inc., an Amgen subsidiary (Nasdaq: AMGN), today announced that a Phase 3 trial evaluating the investigational use of NEXAVAR® (sorafenib) tablets as an adjuvant treatment for patients with hepatocellular carcinoma (HCC), or liver cancer, who had no detectable disease after surgical resection or local ablation, did not meet its primary endpoint of improving recurrence-free survival.

11 Mar 2014

Tissue analysis near tumors holds promise for earlier detection, new treatments

Seemingly healthy cells may in fact hide clues that lung cancer will later develop, according to a study led by researchers at The University of Texas MD Anderson Cancer Center The research is published online in the Journal of the National Cancer Institute.

9 Mar 2014

Agenus reports net loss attributable to common stockholders of $5.8 million for Q4 2013

Agenus Inc., a biopharmaceutical company developing a portfolio of immuno-oncology candidates, including checkpoint modulators (CPMs), heat shock protein vaccines and adjuvants, today announced its financial results and business highlights for the fourth quarter and year ended December 31, 2013.

5 Mar 2014

Researchers find antibody that may be used in future treatments for recurrent small-cell lung cancer

Researchers at Norris Cotton Cancer Center have found an antibody that may be used in future treatments for recurrent small-cell lung cancer, which currently has no effective therapy.

5 Mar 2014

Mcl-1 protein enables NSCLC to survive radiation and drug treatments

Researchers at the Translational Genomics Research Institute have discovered a protein, Mcl-1, that helps enable one of the most common and deadly types of cancer to survive radiation and drug treatments.

5 Mar 2014

GTx provides clinical updates, reports financial results for fourth quarter and full year 2013

GTx, Inc. today provided a Company update and reported financial results for the fourth quarter and full year 2013.

4 Mar 2014

H4 receptor activation plays part in NSCLC progression

Histamine H4 receptor activation decreases epithelial-to-mesenchymal transmission in non-small-cell lung cancer, Chinese research shows.

27 Feb 2014

Motesanib boosts carboplatin/paclitaxel efficacy in NSCLC

Adding motesanib to carboplatin/paclitaxel significantly improves overall survival in Asian patients with nonsquamous non-small-cell lung cancer compared with carboplatin/paclitaxel alone, researchers report.

27 Feb 2014

Study explores influence of reproductive, hormonal factors on overall survival of women with NSCLC

Survival among people with lung cancer has been better for women than men, and the findings of a recent study indicate that female hormones may be a factor in this difference.

26 Feb 2014

Novel SCLC tumour suppressor gene discovered

Inactivation of the MYC-associated factor X gene, MAX, may play a significant role in the development of small-cell lung cancer, scientists believe.

26 Feb 2014

Biothera’s Phase 2b clinical trial in NSCLC presented at International Association for the Study of Lung Cancer

Biothera presented results of its Phase 2b clinical trial in non-small cell lung cancer (NSCLC) this past weekend to top clinicians and scientists at the invitation-only International Association for the Study of Lung Cancer meeting on targeted therapies in Santa Monica, CA.

26 Feb 2014

Unusual EGFR mutation should influence advanced NSCLC treatment choice

Non-small-cell lung cancer patients with very unusual epidermal growth factor receptor mutations may be more likely to be benefit from first-line chemotherapy than a tyrosine kinase inhibitor, research suggests.

25 Feb 2014

Small Cell Lung Cancer News and Research

Lung cancer spread ‘uncommon’ outside of tumour-bearing segment

NSCLC gene fusion testing, targeted crizotinib – not yet cost effective

Investigational vaccine reduces number of tumors in mice with lung cancer

Researchers use "big data" analytics to predict triple-negative breast cancer and other cancers with 95% accuracy

Findings reveal potential drug targets for small cell lung cancer

AnaptysBio announces strategic immuno-oncology collaboration with TESARO

Synta Pharmaceuticals' Hsp90 inhibitor ganetespib selected for study in I-SPY 2 TRIAL

Exosome Diagnostics closes Series B financing round with the raising of $27 million

Bayer and Onyx announce Phase 3 trial evaluating use of NEXAVAR for patients with HCC after local ablation

Tissue analysis near tumors holds promise for earlier detection, new treatments

Agenus reports net loss attributable to common stockholders of $5.8 million for Q4 2013

Researchers find antibody that may be used in future treatments for recurrent small-cell lung cancer

Mcl-1 protein enables NSCLC to survive radiation and drug treatments

GTx provides clinical updates, reports financial results for fourth quarter and full year 2013

H4 receptor activation plays part in NSCLC progression

Motesanib boosts carboplatin/paclitaxel efficacy in NSCLC

Study explores influence of reproductive, hormonal factors on overall survival of women with NSCLC

Novel SCLC tumour suppressor gene discovered

Biothera’s Phase 2b clinical trial in NSCLC presented at International Association for the Study of Lung Cancer

Unusual EGFR mutation should influence advanced NSCLC treatment choice

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News